CXCL13 and B-cell chronic lymphocytic leukemia: In vivo ibrutinib treatment leads to reduced serum levels of a variety of chemokines and inflammatory cytokines in CLL patients as well as decreased chemoattraction of CLL cells through inhibiting CXCL13 secretion by macrophages (Niemann et al., 2016).